Form 4: Dyne Therapeutics CEO Sells Shares for Tax Withholding

Dyne Therapeutics CEO John Cox sold 3,311 shares of common stock to cover tax withholding obligations related to vesting restricted stock units, as disclosed in a Form 4 filing.

Summary

• John Cox, CEO and President of Dyne Therapeutics, Inc., reported a transaction on May 13, 2026.
• He sold 3,311 shares of common stock at a weighted average price of $18.36 per share.
• This sale was to satisfy tax withholding obligations upon the vesting of restricted stock units granted on February 12, 2026.
• The transaction was conducted under a pre-arranged plan consistent with Rule 10b5-1(c) for affirmative defense.
• Following the transaction, Cox beneficially owns 370,834 shares of common stock directly.
• Additionally, he holds 18,000 shares indirectly through four separate trusts for the benefit of a child.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale is for tax withholding purposes under a pre-established plan and does not necessarily reflect a negative view on the company's prospects.

Positives

• The sale was executed under a Rule 10b5-1(c) plan, indicating pre-planned and non-discretionary activity.
• The CEO retains a significant beneficial ownership of 370,834 shares directly, plus shares held in trust.

Negatives

• A portion of the CEO's shares were sold, reducing his direct holdings.

Risks

• The filing does not explicitly mention any new or evolving risks beyond standard disclosures inherent in a Form 4.

Future Outlook

The filing is a statement of changes in beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future financial performance.

Management Comments

• The sale was automatically executed to satisfy tax withholding obligations in connection with the vesting of restricted stock units.
• The automatic sale is provided for in a restricted stock unit agreement constituting a 'binding contract' consistent with the affirmative defense to liability under Rule 10b5-1.
• The sale does not represent a discretionary trade by the Reporting Person.

Industry Context

StockSavvy.ai notes that insider sales for tax withholding purposes are common events, especially following the vesting of equity awards. The key is to distinguish these from discretionary sales, which could signal a lack of confidence in the company's future prospects. The adherence to a Rule 10b5-1 plan in this instance suggests a pre-determined and routine event.

Stakeholder Impact

• Shareholders: The sale is a routine event for tax purposes and is unlikely to have a significant direct impact on the share price, especially given the adherence to a Rule 10b5-1 plan.

Next Steps

• Continued monitoring of insider transactions for any discretionary sales or purchases.

Key Dates

Keywords

Dyne Therapeutics, DYN, Form 4, Insider Trading, Stock Sale, Tax Withholding, Restricted Stock Units, CEO, Beneficial Ownership, Rule 10b5-1